166 related articles for article (PubMed ID: 37500962)
1. Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes.
Clelland EN; Rothschild HT; Patterson A; Molina-Vega J; Kaur M; Symmans WF; Schwartz CJ; Chien AJ; Benz CC; Mukhtar RA
Breast Cancer Res Treat; 2023 Nov; 202(2):367-375. PubMed ID: 37500962
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
Kinsella MD; Nassar A; Siddiqui MT; Cohen C
Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
[TBL] [Abstract][Full Text] [Related]
3. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
[TBL] [Abstract][Full Text] [Related]
4. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
Khabaz MN
Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
[TBL] [Abstract][Full Text] [Related]
6. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.
Fournier A; Fabre A; Mesrine S; Boutron-Ruault MC; Berrino F; Clavel-Chapelon F
J Clin Oncol; 2008 Mar; 26(8):1260-8. PubMed ID: 18323549
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Coexisting Lobular Carcinoma In Situ With Invasive Lobular Carcinoma.
Harbhajanka A; Lamzabi I; Syed S; Jain R; Ghai R; Reddy VB; Bitterman P; Gattuso P
Appl Immunohistochem Mol Morphol; 2016; 24(10):738-743. PubMed ID: 26574630
[TBL] [Abstract][Full Text] [Related]
8. The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.
Gamrani S; Boukansa S; Benbrahim Z; Mellas N; Fdili Alaoui F; Melhouf MA; Bouchikhi C; Banani A; Boubbou M; Bouhafa T; El Fatemi H
Breast J; 2022; 2022():9238804. PubMed ID: 35711896
[TBL] [Abstract][Full Text] [Related]
9. Expression of DDR1 and DVL1 in invasive ductal and lobular breast carcinoma does not correlate with histological type, grade and hormone receptor status.
Ameli F; Rose IM; Masir N
Asian Pac J Cancer Prev; 2015; 16(6):2385-90. PubMed ID: 25824769
[TBL] [Abstract][Full Text] [Related]
10. Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.
Mukhtar RA; Krings G; Chen YY; Mamounas ME; Fahrner-Scott K; Wong J; Alvarado M; Ewing C; Esserman LJ; Rugo H
Breast Cancer Res Treat; 2020 May; 181(1):23-29. PubMed ID: 32240457
[TBL] [Abstract][Full Text] [Related]
11. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
[TBL] [Abstract][Full Text] [Related]
12. Survival analysis in patients with invasive lobular cancer and invasive ductal cancer according to hormone receptor expression status in the Korean population.
Kwon D; Ko BK; Jung SP; Kim HK; Kim EK; Jung YS; Youn HJ; Lee SB
PLoS One; 2022; 17(1):e0262709. PubMed ID: 35051228
[TBL] [Abstract][Full Text] [Related]
13. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
[TBL] [Abstract][Full Text] [Related]
14. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
[TBL] [Abstract][Full Text] [Related]
15. Invasive pleomorphic lobular carcinoma, negative for ER, PR and Her/2neu--a case report.
Manucha V; Khilko N; Reilly K; Zhang X
Int J Clin Exp Pathol; 2011 Jan; 4(2):200-5. PubMed ID: 21326816
[TBL] [Abstract][Full Text] [Related]
16. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
17. [Invasive lobular carcinoma of basal-like subtype of breast: a clinicopathologic analysis].
Zhang LY; Gao LX; Liu G; Yang GZ; Cheng J; Ding HY
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):599-603. PubMed ID: 24314245
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of pleomorphic lobular carcinoma versus invasive lobular carcinoma.
Haque W; Arms A; Verma V; Hatch S; Brian Butler E; Teh BS
Breast; 2019 Feb; 43():67-73. PubMed ID: 30496936
[TBL] [Abstract][Full Text] [Related]
19. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
[TBL] [Abstract][Full Text] [Related]
20. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
De La Cruz LM; Harhay MO; Zhang P; Ugras S
Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]